{"filing":{"accession_number":"0001193125-26-372456","cik":"0001061983","ticker":"CYTK","company_name":"CYTOKINETICS INC","form":"8-K","filing_date":"2026-08-28","report_date":"2026-08-28","primary_document":"cytk-20260828.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1061983/000119312526372456/cytk-20260828.htm"},"events":[{"id":30233,"run_id":27714,"accession_number":"0001193125-26-372456","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Cytokinetics announced positive Phase 3 clinical trial results for aficamten (ACACIA-HCM) in non-obstructive hypertrophic cardiomyopathy, with plans to submit a supplemental New Drug Application to the FDA in Q4 2026. While this is a significant clinical and regulatory milestone for the company's pipeline, it does not fit neatly into the earnings_release category (which typically covers financial results) nor any other specific event type. The disclosure centers on a material clinical development and regulatory milestone that would affect investor assessment of the company's prospects, making it a material operational/strategic event.","company_name":"CYTOKINETICS INC","ticker":"CYTK","filing_date":"2026-08-28","form":"8-K","submitted_at":null,"items":[{"id":32776,"accession_number":"0001193125-26-372456","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Cytokinetics announced positive Phase 3 clinical trial results for aficamten (ACACIA-HCM) in non-obstructive hypertrophic cardiomyopathy, with plans to submit a supplemental New Drug Application to the FDA in Q4 2026. While this is a significant clinical and regulatory milestone for the company's pipeline, it does not fit neatly into the earnings_release category (which typically covers financial results) nor any other specific event type. The disclosure centers on a material clinical development and regulatory milestone that would affect investor assessment of the company's prospects, making it a material operational/strategic event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T13:23:38.381327+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32776,"accession_number":"0001193125-26-372456","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Cytokinetics announced positive Phase 3 clinical trial results for aficamten (ACACIA-HCM) in non-obstructive hypertrophic cardiomyopathy, with plans to submit a supplemental New Drug Application to the FDA in Q4 2026. While this is a significant clinical and regulatory milestone for the company's pipeline, it does not fit neatly into the earnings_release category (which typically covers financial results) nor any other specific event type. The disclosure centers on a material clinical development and regulatory milestone that would affect investor assessment of the company's prospects, making it a material operational/strategic event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T13:23:38.381327+00:00","company_name":"CYTOKINETICS INC","ticker":"CYTK","filing_date":"2026-08-28"}]}